Compare Adaptive Biotechnologies Corp (ADPT) vs Agilysys Inc (AGYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Agilysys Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Agilysys Inc trades at $104.97 (market cap $3.00B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AGYS | |
|---|---|---|
Market Cap | $4.04B | $3.00B |
Sector | Health | Technology |
52-Week High | $25.45 | $141.12 |
52-Week Low | $12.30 | $62.19 |
Enterprise Value | $4.10B | $2.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Agilysys (AGYS) trades at $104.92, down 1.93% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2027 earnings beat expectations, driven by subscription growth and record revenue, prompting raised full-year guidance. The stock shows robust fundamentals with a 63.06% gross margin and 12.99% net income margin, though valuations are elevated with a P/E of 70.01. Institutional sentiment is positive, with all 9 analysts rating it a Buy and a consensus price target of $118.33.
Outlook remains favorable due to earnings momentum and AI-driven hospitality solutions, but risks include high valuation sensitivity and competitive pressures. Upside potential is supported by analyst targets, yet investors should monitor execution on growth forecasts and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →
